Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESRRG | P62508 | 20/20 | 0.98 |
| ▸ | ESRRB | O95718 | 10/20 | 0.84 |
| ▸ | ESR1 | P03372 | 7/20 | 0.84 |
| ▸ | ESRRA | P11474 | 2/20 | 0.78 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.73 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24354483 | 0.96 | ESRRG (0.91) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842168 | 0.94 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL21026578 | 0.93 | ESRRG (0.85) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842053 | 0.92 | ESRRG (1.00) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20978480 | 0.90 | ESRRG (0.84) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL30065746 | 0.89 | ESRRG (0.78) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842127 | 0.89 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL24118908 | 0.88 | ESRRG (0.77) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842100 | 0.88 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 | |
| SCHEMBL20842117 | 0.86 | ESRRG (0.98) | ESRRGESRRBESR1ESRRAKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4192461-A1 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME | NovMetaPharma Co., Ltd. (KR) | 2023-06-14 | — | — | EP | disclosed |
| CN-116113409-A | Methods of treatment for cytokine release syndrome | 诺麦塔制药有限公司 | 2023-05-12 | — | — | CN | disclosed |
| EP-4168013-A1 | METHOD FOR TREATMENT OF PANCREATITIS | NovMetaPharma Co., Ltd. (KR) | 2023-04-26 | — | — | EP | disclosed |
| CN-115996724-A | Method for treating pancreatitis | 诺麦塔制药有限公司 | 2023-04-21 | — | — | CN | disclosed |
| EP-3480186-B1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO LTD (KR) | 2022-06-15 | — | — | EP | disclosed |
| EP-3459936-B1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | DAEGU GYEONGBUK MEDICAL INNOVATION FOUND (KR) | 2022-04-27 | — | — | EP | disclosed |
| US-20220040171-A1 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME | NovMetaHealth Co., Ltd (KR) | 2022-02-10 | — | — | US | disclosed |
| US-20210393583-A1 | METHOD FOR THE TREATMENT OF PANCREATITIS | NOVMETAHEALTH CO., LTD. (KR) | 2021-12-23 | — | — | US | disclosed |
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | DAEGU-GYEONGBUK MEDICAL INNOVATION FOUNDATION (KR) | 2021-03-02 | — | — | US | disclosed |
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | HWANG SUNG YEOUN (KR) | 2019-06-06 | — | — | US | disclosed |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | NOVMETAPHARMA CO., LTD. (KR) | 2019-05-30 | — | — | US | disclosed |
| EP-3480186-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-05-08 | — | — | EP | disclosed |
| EP-3459936-A1 | NOVEL ARYL ETHANE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | Kemimedi Co. Ltd (KR) | 2019-03-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190167820-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | ESRRG 1/4885ESRRB 5/4885ESR1 3/4885 |
| US-20220040171-A1 | METHOD FOR TREATMENT OF CYTOKINE RELEASE SYNDROME | IL1B, IL1A, CCL11 | ESRRG 1686/4885ESRRB 1806/4885ESR1 2124/4885 |
| US-20210393583-A1 | METHOD FOR THE TREATMENT OF PANCREATITIS | PNLIP, AMY2A, CEL | ESRRG 2148/4885ESRRB 1890/4885ESR1 2923/4885 |
| US-20190161490-A1 | NOVEL ARYL ETHENE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | ESRRG, ESR2, ESR1 | ESRRG 1/4885ESRRB 5/4885ESR1 3/4885 |
| US-10934303-B2 | Aryl ethene derivative and pharmaceutical composition containing same as active ingredient | ESRRG, ESR1, ESR2 | ESRRG 1/4885ESRRB 5/4885ESR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.